Pascal Minini
Sanofi R&D
Chilly, France
Chilly, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: December 23, 2024
Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses.
Journal: Molecular genetics and metabolism
Published: January 10, 2024
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Journal: The Lancet. Neurology
Published: March 09, 2023
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.
Journal: Kidney medicine
Published: October 07, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: June 24, 2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Journal: Brain : a journal of neurology
Published: February 16, 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
Journal: Journal of Parkinson's disease
Published: December 13, 2021
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Journal: Atherosclerosis
Published: September 28, 2018
An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.
Journal: Journal of biopharmaceutical statistics
Published: April 05, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Journal: Journal of clinical lipidology
Published: November 28, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.
Journal: Coronary artery disease
Published: October 15, 2016
Economic Burden of Hepatitis in South Korea.
Journal: Japanese journal of infectious diseases
Published: August 19, 2016
Last Updated: 09/26/2026